JP2017511327A5 - - Google Patents

Download PDF

Info

Publication number
JP2017511327A5
JP2017511327A5 JP2016560336A JP2016560336A JP2017511327A5 JP 2017511327 A5 JP2017511327 A5 JP 2017511327A5 JP 2016560336 A JP2016560336 A JP 2016560336A JP 2016560336 A JP2016560336 A JP 2016560336A JP 2017511327 A5 JP2017511327 A5 JP 2017511327A5
Authority
JP
Japan
Prior art keywords
composition
subject
related antigen
administration
months
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016560336A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017511327A (ja
JP6655549B2 (ja
Filing date
Publication date
Priority claimed from GBGB1405921.6A external-priority patent/GB201405921D0/en
Application filed filed Critical
Publication of JP2017511327A publication Critical patent/JP2017511327A/ja
Publication of JP2017511327A5 publication Critical patent/JP2017511327A5/ja
Application granted granted Critical
Publication of JP6655549B2 publication Critical patent/JP6655549B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016560336A 2014-04-02 2015-04-02 免疫応答を誘導するための新規方法 Expired - Fee Related JP6655549B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1405921.6 2014-04-02
GBGB1405921.6A GB201405921D0 (en) 2014-04-02 2014-04-02 Novel methods for inducing an immune response
PCT/EP2015/057423 WO2015150567A1 (en) 2014-04-02 2015-04-02 Novel methods for inducing an immune response

Publications (3)

Publication Number Publication Date
JP2017511327A JP2017511327A (ja) 2017-04-20
JP2017511327A5 true JP2017511327A5 (cg-RX-API-DMAC7.html) 2018-05-17
JP6655549B2 JP6655549B2 (ja) 2020-02-26

Family

ID=50737873

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016560336A Expired - Fee Related JP6655549B2 (ja) 2014-04-02 2015-04-02 免疫応答を誘導するための新規方法
JP2016559965A Active JP6645982B2 (ja) 2014-04-02 2015-04-02 免疫応答を誘導するための新規の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016559965A Active JP6645982B2 (ja) 2014-04-02 2015-04-02 免疫応答を誘導するための新規の方法

Country Status (18)

Country Link
US (3) US10688168B2 (cg-RX-API-DMAC7.html)
EP (2) EP3125930B1 (cg-RX-API-DMAC7.html)
JP (2) JP6655549B2 (cg-RX-API-DMAC7.html)
KR (2) KR102762440B1 (cg-RX-API-DMAC7.html)
CN (2) CN106456738B (cg-RX-API-DMAC7.html)
AR (1) AR099960A1 (cg-RX-API-DMAC7.html)
AU (1) AU2015239025B2 (cg-RX-API-DMAC7.html)
BE (1) BE1022355B1 (cg-RX-API-DMAC7.html)
BR (2) BR112016022463A2 (cg-RX-API-DMAC7.html)
CA (2) CA2943007C (cg-RX-API-DMAC7.html)
EA (1) EA037405B1 (cg-RX-API-DMAC7.html)
ES (2) ES2961840T3 (cg-RX-API-DMAC7.html)
GB (1) GB201405921D0 (cg-RX-API-DMAC7.html)
IL (1) IL247493B (cg-RX-API-DMAC7.html)
MX (3) MX2016012982A (cg-RX-API-DMAC7.html)
SG (1) SG11201607086QA (cg-RX-API-DMAC7.html)
WO (2) WO2015150568A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201605955B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
GB201621686D0 (en) * 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB2600654B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel devices
MX2020005481A (es) 2017-12-01 2020-12-07 Glaxosmithkline Biologicals Sa Purificacion de saponina.
US20220235095A1 (en) 2019-06-05 2022-07-28 Glaxosmithkline Biologicals Sa Saponin purification
CN113125756B (zh) * 2020-07-15 2022-10-25 南京岚煜生物科技有限公司 抗体标准品赋值和抗原中和当量确定的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US152200A (en) * 1874-06-16 Improvement in garters
US1002607A (en) * 1905-08-28 1911-09-05 John Willard Taylor Paper pulley.
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
ES2594758T3 (es) 2002-10-23 2016-12-22 Glaxosmithkline Biologicals S.A. Procedimientos de vacunación contra la malaria
MX2007004031A (es) 2004-10-14 2007-11-08 Crucell Holland Bv Vacunas de cebado/refuerzo contra el paludismo.
EP2457926B1 (en) * 2005-04-29 2014-09-24 GlaxoSmithKline Biologicals S.A. Novel method for preventing or treating M. tuberculosis infection
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
CA2668100C (en) * 2006-11-01 2014-12-23 Immport Therapeutics, Inc. Compositions and methods for immunodominant antigens
MX2009009342A (es) * 2007-03-02 2009-09-11 Glaxosmithkline Biolog Sa Metodo novedoso y composiciones.
TW200908994A (en) * 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
ES2647321T3 (es) * 2008-07-25 2017-12-20 Glaxosmithkline Biologicals S.A. Composiciones y procedimientos novedosos
LT2315834T (lt) * 2008-07-25 2018-09-10 Glaxosmithkline Biologicals S.A. Tuberkuliozės rv2386c baltymas, kompozicijos ir jų panaudojimas
HUE031044T2 (en) * 2008-07-25 2017-06-28 Glaxosmithkline Biologicals Sa Polypeptides, polynucleotides and compositions for use in the treatment of latent tuberculosis
HRP20161608T1 (hr) * 2010-01-27 2017-01-13 Glaxosmithkline Biologicals Sa Modificirani tuberkulozni antigeni
HUE045766T2 (hu) * 2010-12-14 2020-01-28 Glaxosmithkline Biologicals Sa Antigén mycobacterium-készítmény
WO2015126930A2 (en) * 2014-02-18 2015-08-27 Stc.Unm Booster drug therapy for mycobacterium infections
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
BR112016023778A2 (pt) * 2014-04-24 2017-10-17 Statens Seruminstitut proteína de fusão ou coquetel antígeno, uso de uma proteína de fusão ou coquetel antígeno, vacina, e método para a imunização de um animal, incluindo um ser humano, contra a tuberculose causada por micobactérias virulentas
GB201513176D0 (en) * 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response

Similar Documents

Publication Publication Date Title
JP2017511327A5 (cg-RX-API-DMAC7.html)
Akache et al. Sulfated archaeol glycolipids: Comparison with other immunological adjuvants in mice
WO2006060710A3 (en) Vaccine formulations for intradermal delivery comprising adjuvants and antigenic agents
JP2008539187A5 (cg-RX-API-DMAC7.html)
BRPI0412444B1 (pt) fração de quil a com baixa toxidez e seu uso
TWI630915B (zh) 無細胞百日咳疫苗
JP2020528911A5 (cg-RX-API-DMAC7.html)
Lowell et al. Back to the future: immunization with M-001 prior to trivalent influenza vaccine in 2011/12 enhanced protective immune responses against 2014/15 epidemic strain
Li et al. Research progress of therapeutic vaccines for treating chronic hepatitis B
JP2017511324A5 (cg-RX-API-DMAC7.html)
JP2015500827A5 (cg-RX-API-DMAC7.html)
RU2014127714A (ru) ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile
JP2015524802A5 (cg-RX-API-DMAC7.html)
RU2015100889A (ru) Вакцины для менингококка серогруппы х
IL276661B2 (en) Immunogenic preparation containing staphylococcal antigens
EP3125930B1 (en) Novel methods for inducing an immune response
CN110621339A (zh) 疫苗接种
JP2018532782A5 (cg-RX-API-DMAC7.html)
Baz et al. Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza vaccines in mice
JP2015529677A5 (cg-RX-API-DMAC7.html)
WO2005074460A3 (en) Methods of enhancing immune response in the intradermal compartment and compounds useful in the methods
US11771757B2 (en) Compositions and methods of manufacturing trivalent filovirus vaccines
Faingezicht et al. Primary and booster vaccination with DTPw-HB/Hib pentavalent vaccine in Costa Rican children who had received a birth dose of hepatitis B vaccine
Sisteré-Oró et al. Influenza NG-34 T cell conserved epitope adjuvanted with CAF01 as a possible influenza vaccine candidate
Acosta et al. TB VACCINES BASED ON PROTEOLIPOSOMES AND LIPOSOMES FROM NON PATHOGENIC MYCOBACTERIA